Novo Holdings A S raised its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 24.1% in the second quarter, according to its most recent 13F filing with the SEC. The fund owned 2,317,870 shares of the biopharmaceutical company’s stock after buying an additional 450,000 shares during the period. Amicus Therapeutics comprises about 4.1% of Novo Holdings A S’s portfolio, making the stock its 6th largest holding. Novo Holdings A S owned 1.01% of Amicus Therapeutics worth $28,927,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. US Bancorp DE increased its stake in shares of Amicus Therapeutics by 50.9% in the 2nd quarter. US Bancorp DE now owns 4,896 shares of the biopharmaceutical company’s stock valued at $61,000 after purchasing an additional 1,651 shares in the last quarter. Meeder Asset Management Inc. purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $73,000. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $122,000. Weil Company Inc. purchased a new position in shares of Amicus Therapeutics in the 2nd quarter valued at about $125,000. Finally, Rockefeller Capital Management L.P. increased its stake in shares of Amicus Therapeutics by 18,246.0% in the 2nd quarter. Rockefeller Capital Management L.P. now owns 11,558 shares of the biopharmaceutical company’s stock valued at $144,000 after purchasing an additional 11,495 shares in the last quarter.
Several brokerages recently weighed in on FOLD. HC Wainwright restated a “buy” rating and issued a $18.00 price target on shares of Amicus Therapeutics in a research note on Thursday, August 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $19.00 price objective (down from $20.00) on shares of Amicus Therapeutics in a report on Wednesday, June 5th. ValuEngine cut Amicus Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, August 12th. BidaskClub cut Amicus Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 6th. Finally, Cowen reiterated a “buy” rating and issued a $31.00 price objective on shares of Amicus Therapeutics in a report on Thursday, August 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Amicus Therapeutics presently has a consensus rating of “Buy” and an average price target of $18.06.
In other news, CEO John F. Crowley sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 11th. The stock was sold at an average price of $10.05, for a total transaction of $201,000.00. Following the transaction, the chief executive officer now directly owns 770,194 shares in the company, valued at approximately $7,740,449.70. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Burke W. Whitman bought 4,945 shares of the stock in a transaction dated Friday, August 23rd. The shares were bought at an average price of $10.07 per share, for a total transaction of $49,796.15. Following the completion of the acquisition, the director now owns 21,612 shares in the company, valued at $217,632.84. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 60,000 shares of company stock worth $701,200. Insiders own 2.50% of the company’s stock.
FOLD stock traded down $0.17 during trading on Wednesday, hitting $9.62. The stock had a trading volume of 22,604 shares, compared to its average volume of 3,765,506. The company has a debt-to-equity ratio of 0.31, a current ratio of 7.09 and a quick ratio of 6.97. Amicus Therapeutics, Inc. has a twelve month low of $8.27 and a twelve month high of $14.61. The stock has a market capitalization of $2.50 billion, a P/E ratio of -7.26 and a beta of 1.65. The company’s 50-day moving average price is $10.43 and its two-hundred day moving average price is $12.21.
Amicus Therapeutics (NASDAQ:FOLD) last issued its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.34). The business had revenue of $44.13 million for the quarter, compared to analysts’ expectations of $41.14 million. Amicus Therapeutics had a negative return on equity of 66.79% and a negative net margin of 336.41%. The business’s revenue for the quarter was up 107.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.33) EPS. As a group, sell-side analysts expect that Amicus Therapeutics, Inc. will post -1.33 EPS for the current fiscal year.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers Galafold, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 for indications, including pompe disease.
Featured Story: What are different types of coverage ratios?
Want to see what other hedge funds are holding FOLD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amicus Therapeutics, Inc. (NASDAQ:FOLD).
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.